Loading...

PE anti-human CD4 Antibody

Pricing & Availability
Clone
RPA-T4 (See other available formats)
Regulatory Status
RUO
Workshop
IV T114
Other Names
T4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
rpa-t4
Human peripheral blood lymphocytes stained with RPA-T4 PE
  • rpa-t4
    Human peripheral blood lymphocytes stained with RPA-T4 PE
  • RPA-T4_PE_CD4_Antibody_2_042922
    Human peripheral blood was stained with CD4 (clone RPA-T4) PE (solid line) or mouse IgG1, κ PE isotype control (dashed line).

    Data was acquired on the Moxi Flow, exported, and processed using FlowJo software.
See PE spectral data
Cat # Size Price Quantity Check Availability Save
300507 25 tests 28 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300508 100 tests 66 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300550 100 µg 146 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300539 500 tests 325 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules, and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RPA-T4 antibody binds to the D1 domain of CD4 (CDR1 and CDR3 epitopes) and can block HIV gp120 binding and inhibit syncytia formation. Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections3,4,5, blocking of T cell activation1,2, and spatial biology (IBEX)10,11.  This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300569 - 300574).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. (Activ)
  2. Moir S, et al. 1999. J. Virol. 73:7972. (Activ)
  3. Deng MC, et al. 1995. Circulation 91:1647. (IHC)
  4. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  5. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  6. Lan RY, et al. 2006. Hepatology 43:729.
  7. Zenaro E, et al. 2009. J. Leukoc. Biol. 86:1393. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Chen J, et al. 2017. Sci Rep. 10.1038/s41598-017-11056-9. PubMed
  2. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  3. Kuo HH, et al. 2018. Immunity. 48:1183. PubMed
  4. Miura M, et al. 2019. Wellcome Open Res. 3:105. PubMed
  5. Tankou SK, et al. 2018. Ann Neurol. 83:1147. PubMed
  6. Franchini DM et al. 2019. Cell reports. 26(1):94-107 . PubMed
  7. Anderson NR, et al. 2019. Cell Adh Migr. 13:163. PubMed
  8. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  9. Xia Y, et al. 2019. Gastroenterol Res Pract. 2019:5436961. PubMed
  10. Zeng Y et al. 2019. Immunity. 51(5):930-948 . PubMed
  11. Gärtner K, et al. 2019. J Extracell Vesicles. 8:1573051. PubMed
  12. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  13. Bagadia P, et al. 2019. Nat Immunol. 20:1174. PubMed
  14. McGinty JW, et al. 2020. Immunity. 52(3):528-541. PubMed
  15. Bhattacharya S, et al. 2020. Front Bioeng Biotechnol. 1.055555556. PubMed
  16. Scott e, et al. 2015. J Immunol. 195: 5561 - 5571. PubMed
  17. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  18. Fu W, et al. 2016. Sci Rep. 6:38162. PubMed
  19. Schank M, et al. 2020. Cell Death Dis. 1.173611111. PubMed
  20. Vanoni G, et al. 2021. eLife. 10:00. PubMed
  21. Bergamaschi L, et al. 2021. Immunity. 54(6):1257-1275.e8. PubMed
  22. Mndez-Mancilla A, et al. 2021. Cell Chemical Biology. 29:321. PubMed
  23. Ziegler CGK, et al. 2021. Cell. 184(18):4713-4733.e22. PubMed
  24. Miller IC, et al. 2021. Nature Biomedical Engineering. :. PubMed
  25. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  26. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  27. Ho CH, et al. 2021. Arthritis Res Ther. 23:199. PubMed
  28. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  29. Paul S, et al. 2021. Sci Transl Med. 13:. PubMed
  30. Lamsfus Calle C, et al. 2021. Front Immunol. 12:625712. PubMed
  31. Liu C, et al. 2021. Cell Res. 31:1106. PubMed
  32. Hu W, et al. 2021. Vaccines (Basel). 9:. PubMed
  33. Chan S, et al. 2022. Nat Cancer. . PubMed
  34. Elston L, et al. 2020. Br J Haematol. 188:872. PubMed
  35. Anderson DA, et al. 2022. J Exp Med. 219:. PubMed
  36. Schlicher L, et al. 2022. Int J Mol Sci. 23:. PubMed
  37. Vabret N, et al. 2022. iScience. 25:104599. PubMed
  38. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  39. Pons S, et al. 2021. Immun Inflamm Dis. 9:1656. PubMed
  40. Namvar N, et al. 2022. Iran J Allergy Asthma Immunol. 21:600. PubMed
  41. Rosenberg JM, et al. 2022. Med (N Y). 3:42. PubMed
  42. Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed
  43. Jenkins E, et al. 2023. Nat Commun. 14:1611. PubMed
  44. Xiao Q, et al. 2023. Bio Protoc. 13:e4655. PubMed
  45. Lee H, et al. 2023. Tuberc Respir Dis (Seoul). . PubMed
RRID
AB_314075 (BioLegend Cat. No. 300507)
AB_314076 (BioLegend Cat. No. 300508)
AB_2564152 (BioLegend Cat. No. 300550)
AB_2562053 (BioLegend Cat. No. 300539)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Dendritic cells, Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 3    Revision Date: 08.31.2016

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account